SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Vector illustration of Retro styled Abstract Businessman caught up in a bureaucratic Spiders Web. Hi-res Jpeg, PNG and PDF files included.
Government
Trump’s Whiplash Policies Keep Pharmas on Their Toes
As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives find themselves faced with policy questions ranging from the Inflation Reduction Act to RFK Jr.
February 12, 2025
 · 
4 min read
 · 
Annalee Armstrong
Podcast
New M&A Action, BMS’ Ongoing Cost Cuts and the Insatiable Demand for Weight Loss Drugs
Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron sues Sanofi over an alleged failure to provide adequate information about Dupixent sales.
February 12, 2025
 · 
1 min read
 · 
Heather McKenzie
Limited resources, profit distribution, resource sharing concept. Three hands with forks and one pie chart. Minimalist collage
GLP-1
Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved into a new pharma stratosphere, far eclipsing their rivals.
February 12, 2025
 · 
2 min read
 · 
Annalee Armstrong
Illustration of a group of businessmen white-collar workers dismissed
Layoffs
Inventiva to Halve Its Workforce, Shift Focus to MASH Candidate
French biotech Inventiva’s layoffs and pipeline shift are expected to help keep the company operational into the second half of 2026.
February 11, 2025
 · 
1 min read
 · 
Angela Gabriel
New York City, NY, USA - August 22, 2022: Pfizer world headquarters in New York City, USA. Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation.
Prostate cancer
Leaked Conference Article Shows Pfizer’s Positive Phase I Prostate Cancer Data
A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating castration-resistant prostate cancer.
February 11, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Medical doctor challenge concept and medicine challenges idea as a physician or pharmacist standing in a desert with medication symbols as a healthcare symbol with 3D illustration elements.
Drug Delivery
Explainer: The Thriving Shadow Market of GLP-1s for Weight Loss
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The situation is causing the FDA regulatory headaches and, more seriously, posing potential risks to the public.
February 11, 2025
 · 
5 min read
 · 
Ben Hargreaves
Novartis' office building in Marburg, Germany
Mergers & acquisitions
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
February 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Merck KGaA signage at its headquarters in Darmstadt, Germany
Mergers & acquisitions
Merck KGaA Courts Cancer Biotech SpringWorks for Potential Buyout
Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential acquisition, though details of its offer have yet to be revealed.
February 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eli Lilly's biotechnology center in California
Collaboration
Lilly Signs Back-to-Back Deals in MASH, Cancer
Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals and another for cancer therapies with Australia’s AdvanCell.
February 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS